Day: June 7, 2023

7 June 2023: The Board of Directors of Hexagon Composites ASA (“Hexagon Composites” or the “Company”) calls for an Extraordinary General Meeting (“EGM”) 28 June 2023 where the Board of Directors requests authorization to distribute up to 25% of the total outstanding shares in Hexagon Purus ASA (“Hexagon Purus”) as a dividend-in-kind to its shareholders. As a result of the share distribution and subject to final EGM approval, Hexagon Composites’ ownership will decrease significantly, and the Company will undertake a non-controlling ownership in Hexagon Purus. The EGM notice is attached as a separate document. “We believe the proposed dividend is in the interest of the shareholders of both Hexagon Composites and Hexagon Purus. Subject to EGM approval of the distribution, Hexagon Composites will achieve financial deconsolidation and increase...

New luxury single-family home community is located just outside Atlanta in prime Marietta locationFreestone Station by Toll Brothers Freestone Station luxury home community by Toll Brothers is coming soon to Marietta, GeorgiaFreestone Station by Toll Brothers “Combining innovative architectural designs with resort-style amenities, Freestone Station provides families the opportunity to experience luxury living with many lifestyle options nearby in desirable Cobb County,” said Eric White, the Division President of Toll Brothers in Atlanta.MARIETTA, Ga., June 07, 2023 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest luxury home community is coming soon to Marietta, Georgia. Freestone Station will feature flexible single-family homes with a wide array...

Stjórn Vátryggingafélags Íslands hf. hefur boðað til hluthafafundar sem haldinn verður í höfuðstöðvum félagsins að Ármúla 3, 108 Reykjavík, miðvikudaginn 14. júní kl. 16:00, en auk þess verður boðið upp á rafræna þátttöku. Hluthafar eða umboðsmenn hluthafa sem hafa hug á því að sækja hluthafafundinn, hvort sem er rafrænt eða á staðnum, eru beðnir um að skrá sig á vefsíðunni:https://www.lumiconnect.com/meeting/visegm2023 Frestur til að skrá sig er til kl. 16:00 þann 12. júní, eða tveimur dögum fyrir hluthafafundinn. Með innskráningu þarf að fylgja mynd af skilríkjum og umboð, ef við á. Endanleg dagskrá fundarins er í viðhengi. Öll gögn vegna hluthafalfundar, s.s. ályktunartillögur stjórnar og greinargerð með þeim, kynning vegna hluthafafundar, skýrslu stjórnar vegna hlutafjárhækkunar, umsögn löggilts endurskoðanda og skýrslu löggilts...

Monthly declaration of the total number of shares and voting rights composing the company’s capital (at May 31st, 2023) This declaration is established in accordance with Article L.233-8 II of the French Code de Commerce and of Article 223-11 of the Règlement Général of the Autorité des marchés financiers (AMF). Date: May 31st, 2023 Total number of shares composing the capital: 37,818,112 Total number of voting rights, gross (1): 38,011,111 Total number of voting rights, net (2): 37,971,864         (1) In accordance with the second paragraph of article 223-11 of the Règlement Général of the AMF, the gross total of voting rights is based on the total number of shares composing the company’s capital which have voting rights, including shares deprived of their voting rights (2) The net total of voting rights is equal to the gross total,...

IR-MED Inc. Dr. Lynn EschenbacherInnovative executive driving positive outcomes and profitability, Dr. Eschenbacher is focused on addressing healthcare access and equity Through early, non-invasive detection of pressure injuries, PressureSafe is poised to save billions in acute care costs and reduce patient deaths from pressure woundsRosh Pina, Israel, June 07, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, announced today the appointment of Lynn Eschenbacher PharmD, MBA, FASHP, CPEL to its Advisory Board. Dr. Eschenbacher is an innovative business development executive with extensive experience in the healthcare industry. As CEO and Founder of Echelon Health Strategies,...

Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a...